150 related articles for article (PubMed ID: 36223184)
1. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.
Chicharro P; Llamas-Velasco M; Armesto S; Herrera Acosta E; Vidal D; Vilarrasa E; Rivera-Diaz R; De-la-Cueva P; Martorell-Calatayud A; Ballescà F; Belinchon I; Carretero G; Rodriguez L; Romero-Maté A; Pujol-Montcusí J; Salgado L; Sahuquillo-Torralba A; Coto-Segura P; Baniandrés Rodríguez O; Feltes R; Riera-Monroig J; Dauden E
Dermatol Ther; 2022 Dec; 35(12):e15929. PubMed ID: 36223184
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study.
Ding Y; Li W; Guan X; Liu N; Zhou Y; Li G; Wang X; Wang Z; Xiao X; Yang B; Lv C; Zhang C; Shi Y
Clin Transl Sci; 2023 Oct; 16(10):1803-1814. PubMed ID: 37644777
[TBL] [Abstract][Full Text] [Related]
4. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting.
Chicharro P; Llamas-Velasco M; Armesto S; Herrera-Acosta E; Vidal D; Vilarrasa E; Rivera R; De la Cueva P; Martorell-Calatayud A; Ballescà F; Belinchón I; Carretero G; Rodríguez L; Romero-Maté A; Pujol-Montcusí J; Salgado L; Sahuquillo-Torralba A; Coto-Segura P; Baniandrés-Rodríguez O; Feltes R; Alsina M; Daudén E
Dermatol Ther; 2022 Aug; 35(8):e15653. PubMed ID: 35731640
[TBL] [Abstract][Full Text] [Related]
5. Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response.
Rompoti N; Sidiropoulou P; Panagakis P; Stratigos A; Papoutsaki M; Stefanaki E; Vavouli C; Politou M; Befon A; Kostakis P; Rigopoulos D; Nicolaidou E
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1240-1247. PubMed ID: 31953892
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Langley RG; Sofen H; Dei-Cas I; Reich K; Sigurgeirsson B; Warren RB; Paul C; Szepietowski JC; Tsai TF; Hampele I; You R; Charef P; Papavassilis C
Br J Dermatol; 2023 Feb; 188(2):198-207. PubMed ID: 36763857
[TBL] [Abstract][Full Text] [Related]
7. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
Ortiz-Salvador JM; Saneleuterio-Temporal M; Magdaleno-Tapial J; Velasco-Pastor M; Pujol-Marco C; Sahuquillo-Torralba A; Mateu-Puchades A; Pitarch-Bort G; Marí-Ruiz JI; Mataix-Díaz J; Montesinos-Villaescusa E; Miralles-Botella J; García-Fernández L; Martorell-Calatayud A; Belinchón-Romero I; Sánchez-Carazo JL; Pérez-Ferriols A
J Am Acad Dermatol; 2019 Aug; 81(2):427-432. PubMed ID: 30872150
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
Augustin M; Sator PG; von Kiedrowski R; Conrad C; Rigopoulos D; Romanelli M; Ghislain PD; Torres T; Ioannides D; Aassi M; Schulz B; Jagiello P;
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1796-1804. PubMed ID: 35696305
[TBL] [Abstract][Full Text] [Related]
9. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of secukinumab in Chinese patients with moderate-to-severe plaque psoriasis: a real-life cohort study.
Zhao Y; Cai L; Liu XY; Zhang H; Zhang JZ
Chin Med J (Engl); 2021 May; 134(11):1324-1328. PubMed ID: 33950871
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
[TBL] [Abstract][Full Text] [Related]
12. Real-world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety.
Asawanonda P; Pattamadilok B; Chularojanamontri L; Chuamanochan M; Choonhakarn C; Chakkavittumrong P; Sangob N; Rajatanavin N
Dermatol Ther; 2022 Dec; 35(12):e15958. PubMed ID: 36279306
[TBL] [Abstract][Full Text] [Related]
13. Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis.
Ziolkowska-Banasik D; Hadas E; Pastuszczak M
J Drugs Dermatol; 2024 Feb; 23(2):74-77. PubMed ID: 38306130
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
Körber A; Thaçi D; von Kiedrowski R; Bachhuber T; Melzer N; Kasparek T; Kraehn-Senftleben G; Amon U; Augustin M
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):411-419. PubMed ID: 28960469
[TBL] [Abstract][Full Text] [Related]
15. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain.
Notario J; Deza G; Vilarrasa E; Valentí F; Muñoz C; Mollet J; Rocamora V; Carrascosa JM; Del Alcázar E; Alsina M; Vidal D; Puig L; López-Ferrer A; Riera J; Gallardo F; Ferran M
J Dermatolog Treat; 2019 Aug; 30(5):424-429. PubMed ID: 30244618
[No Abstract] [Full Text] [Related]
16. Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
Magnolo N; Kingo K; Laquer V; Browning J; Reich A; Szepietowski JC; Keefe D; Papanastasiou P; Bao W; Forrer P; Patekar M
Paediatr Drugs; 2022 Jul; 24(4):377-387. PubMed ID: 35698000
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study.
Megna M; Di Costanzo L; Argenziano G; Balato A; Colasanti P; Cusano F; Galluccio AG; Gambardella A; Lembo S; Mozzillo R; Scotto Di Luzio G; Fabbrocini G; Balato N
Expert Opin Biol Ther; 2019 Aug; 19(8):855-861. PubMed ID: 31140882
[No Abstract] [Full Text] [Related]
19. Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real-world practice.
Zhou J; Yuan Y; Liu Y; Chu M; Liu H; Liu Q; Wang R; Shao S; Wang G; Yu C
Exp Dermatol; 2024 Jan; 33(1):e14890. PubMed ID: 37474877
[TBL] [Abstract][Full Text] [Related]
20. Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single-center, uncontrolled, prospective study in 36 weeks.
Chen XB; Zheng YX; Ye LR; Chen XY; Man XY
Dermatol Ther; 2022 Dec; 35(12):e15911. PubMed ID: 36209377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
